Campos et al. [24] observed heterogeneous flow cytometric expression of BCL2 among 82 patients with de novo AML, but patients with >20% BCL2-positive leukemic cells had significantly lower CR rates and shorter survival. The gene discussed is BCL2; the disease is acute myeloid leukemia.